<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04239755</url>
  </required_header>
  <id_info>
    <org_study_id>Doxycycline effects on TBI</org_study_id>
    <nct_id>NCT04239755</nct_id>
  </id_info>
  <brief_title>Doxycycline in Acute Traumatic Brain Injury</brief_title>
  <official_title>Doxycycline Effects on Neurological Outcomes in Patients With Acute Traumatic Brain Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Damanhour University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tanta University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Damanhour University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      evaluate the impact of Doxycycline on both clinical outcome and blood levels of NSE in
      patients with TBI.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Approval will be obtained from Research Ethics Committee of Faculty of Pharmacy,
           Damnhour University.

        2. All Participants agreed to take part in this clinical research and provide informed
           consent. for unconscious participants, the informed consent was obtained from their
           legally authorized representative.

        3. Patients with moderate to severe TBI will be enrolled from Tanta university hospitals.

        4. Serum samples will be collected for measuring the biomarkers.

        5. Our design is randomized, controlled study.

        6. All enrolled patients will be divided into 2 groups, Group (1) 25 patients that receive
           doxycycline 100 mg twice daily, either orally or through a nasogastric tube for 5 days,
           and group (2) will be 25 patients will receive placebo in addition to the standard
           treatment.

        7. All patients will be followed up during ICU period.

        8. Statsicial tests appropriate to the study design will be conducted to evaluate the
           significance of the results.

        9. Measuring outcome: the primary outcome is the change in the serum level of acute brain
           injury biomarkers.

       10. Results, conclusions, discussion and recommendations will be given.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 15, 2019</start_date>
  <completion_date type="Actual">June 24, 2020</completion_date>
  <primary_completion_date type="Actual">June 20, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Neuron specific enolase</measure>
    <time_frame>7 days</time_frame>
    <description>levels of NSE</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Glasgow Coma Scale (GCS)</measure>
    <time_frame>7 days</time_frame>
    <description>Glasgow Coma Scale (GCS) 15 Points: Normal 3-14 Points: Abnormal</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Traumatic Brain Injury</condition>
  <arm_group>
    <arm_group_label>Doxycycline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group (1) 25 patients that receive doxycycline 100 mg twice daily, either orally or through a nasogastric tube for 5 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>group (2) will be 25 patients will receive placebo in addition to the standard treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxycycline 100 MG Oral Tablet</intervention_name>
    <description>doxycycline 100 mg twice daily, either orally or through a nasogastric tube for 5 day</description>
    <arm_group_label>Doxycycline</arm_group_label>
    <other_name>vibramycine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo in addition to the standard treatment.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Hospital admission in the first 24 h of injury,

          2. 18 to 90 years of age and

          3. Both sexes with moderate to severe traumatic brain injury (GCS score â‰¤ 12).

          4. Able to tolerate enteral feeding and drug administration within the first 24 hours of
             TBI

        Exclusion Criteria:

          1. Hypersensitivity to tetracyclines

          2. Pregnant and breast feeding women,

          3. History of autoimmune disease.

          4. History of receiving chronic steroid treatment and isotretinoin,

          5. Pre-existing hepatic (AST, ALT greater than 3 times the upper limit of normal) or
             renal failure (BUN/ Creatinine 20:1; creatinine &gt; 2 mg/dL),

          6. Known malignancies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Noha Mansour, Lecturer</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mansoura University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tanta University Hospital</name>
      <address>
        <city>Tanta</city>
        <state>El-Gharbia</state>
        <zip>31527</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <results_reference>
    <citation>Sanchez Mejia RO, Ona VO, Li M, Friedlander RM. Minocycline reduces traumatic brain injury-mediated caspase-1 activation, tissue damage, and neurological dysfunction. Neurosurgery. 2001 Jun;48(6):1393-9; discussion 1399-401.</citation>
    <PMID>11383749</PMID>
  </results_reference>
  <results_reference>
    <citation>Janata A, Magnet IA, Schreiber KL, Wilson CD, Stezoski JP, Janesko-Feldman K, Kochanek PM, Drabek T. Minocycline fails to improve neurologic and histologic outcome after ventricular fibrillation cardiac arrest in rats. World J Crit Care Med. 2019 Nov 19;8(7):106-119. doi: 10.5492/wjccm.v8.i7.106. eCollection 2019 Nov 19.</citation>
    <PMID>31853446</PMID>
  </results_reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>January 21, 2020</study_first_submitted>
  <study_first_submitted_qc>January 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 27, 2020</study_first_posted>
  <last_update_submitted>June 24, 2020</last_update_submitted>
  <last_update_submitted_qc>June 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Damanhour University</investigator_affiliation>
    <investigator_full_name>Rehab Werida</investigator_full_name>
    <investigator_title>Clinical Pharmacy Lecturer</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Brain Injuries, Traumatic</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxycycline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

